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Introduction
Neutralizing antibodies are an important component of
the humoral immune response directed against viral
infections So far the few available anti HIV-1 broadly
neutralizing antibodies have a limited breadth and
potency against clade C viruses. More than 50% of the
HIV-1 infections worldwide belong to clade C. Clade C
is the most prevalent subtype in India.
Materials and methods
A human scFv phage display library was constructed from
the peripheral blood mononuclear cells of an HIV-1 Clade
C infected Indian patient, having a good titre of serum
neutralizing antibodies. Diversity of the scFv library was
checked by sequencing and DNAfingerprinting analysis of
randomly selected clones from the preselected library.
One round of biopanning was done against V3 peptide of
clade C and clade B. Single chain fragments were checked
for their soluble expression in E. coli HB2151 and purfied
using Ni+2 affinity colums. Specificity of the soluble scFvs
was checked by indirect ELISA. Single chain fragments
were checked for their stability in different agents like 30%
DMSO. 4M NaCl, pH 2-11.
Results
50 clones were randomly selected after biopanning and
they were checked for their binding to V3C and V3B pep-
tides. In phage ELISA 15 out of 50 clones showed binding
to both the V3 peptides. A 32kDa band was observed in
polyacrylamide gel electrophoresis as predicted. The
expressed product was confirmed by Western blot analysis
using anti His Tag antibody. Specificity of the purified
scFvs was confirmed by their binding to V3 peptides and
no reactivity against other unrelated peptides. Further
these scFvs displayed a stable binding to V3 peptides in
different denaturing agents.
Conclusions
This is the first study to generate human anti-V3 scFvs
against HIV-1 clade C. Further characterization of these
scFvs for their neutralization potential will help identify
unique and shared epitopes responsible for neutraliza-
tion of clade C and non clade C viruses.
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